Predicting mortality and hospital admission in patients with COPD: Significance of NT pro-BNP, clinical and echocardiographic assessment

Journal of Cardiovascular Medicine

Volumn 12, Issue 9, 2011, Pages 613-618

  Gale, Chris P ^a,b   White, John E S ^b   Hunter, Alan ^b   Owen, Jane ^b   Allen, Jane ^b   Watson, Josie ^b   Holbrook, Ian ^b   Durham, Nigel P ^b   Pye, Maurice P ^b  

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b YORK TEACHING HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

chronic obstructive airways disease; hospitalization; mortality; NT pro BNP

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT;

AGED; AORTA STENOSIS; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; ECHOCARDIOGRAPHY; FEMALE; FOLLOW UP; HEART ATRIUM FIBRILLATION; HEART LEFT ATRIUM; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HEART RIGHT VENTRICLE FAILURE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; OXYGEN THERAPY; PREDICTIVE VALUE; PROTEIN FUNCTION; SMOKING; SURVIVAL; SYSTOLIC DYSFUNCTION;

AGED; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CHI-SQUARE DISTRIBUTION; ECHOCARDIOGRAPHY, DOPPLER; ENGLAND; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LENGTH OF STAY; LOGISTIC MODELS; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PATIENT ADMISSION; PEPTIDE FRAGMENTS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSPECTIVE STUDIES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; UP-REGULATION;

EID: 80051798124     PISSN: 15582027     EISSN: 15582035     Source Type: Journal    
DOI: 10.2459/JCM.0b013e3283491780     Document Type: Article

References (33)

1. de Bold AJ, Bruneau BG, Kuroski de Bold ML. Mechanical and neuroendocrine regulation of the endocrine heart. Cardiovasc Res 1996; 31:7-18. (Pubitemid 26093751)
2. Dickstein K. Natriuretic peptides in detection of heart failure. Lancet 1998; 351:4. (Pubitemid 28020153)
3. Nishikimi T, Kuwahara K, Nakao K. Current biochemistry, molecular biology, and clinical relevance of natriuretic peptides. J Cardiol 2011; 57:131-140.
4. Bando M, Ishii Y, Sugiyama Y, et al. Elevated plasma brain natriuretic peptide levels in chronic respiratory failure with cor pulmonale. Respir Med 1999; 93:507-514. (Pubitemid 29364066)
5. Inoue Y, Kawayama T, Iwanaga T, et al. High plasma brain natriuretic peptide levels in stable COPD without pulmonary hypertension or cor pulmonale. Intern Med 2009; 48:503-512.
6. Leuchte HH, Baumgartner RA, Nounou ME, et al. Brain natriuretic peptide is a prognostic parameter in chronic lung disease. Am J Respir Crit Care Med 2006; 173:744-750.
7. Bozkanat E, Tozkoparan E, Baysan O, et al. The significance of elevated brain natriuretic peptide levels in chronic obstructive pulmonary disease. J Int Med Res 2005; 33:537-544. (Pubitemid 41388392)
8. Casserly B, Klinger JR. Brain natriuretic peptide in pulmonary arterial hypertension: biomarker and potential therapeutic agent. Drug Des Devel Ther 2009; 3:269-287.
9. Morrison LK, Harrison A, Krishnaswamy P, et al. Utility of a rapid Bnatriuretic peptide assay in differentiating congestive heart failure from lung disease in patients presenting with dyspnea. J Am Coll Cardiol 2002; 39:202-209. (Pubitemid 34084622)
10. Gemici G, Erdim R, Celiker A, et al. B-type natriuretic peptide levels in patients with COPD and normal right ventricular function. Adv Ther 2008; 25:674-680.
11. Omland T, Hagve TA. Natriuretic peptides: physiologic and analytic considerations. Heart Fail Clin 2009; 5:471-487.
12. Loke I, Squire IB, Davies JE, et al. Reference ranges for natriuretic peptides for diagnostic use are dependent on age, gender and heart rate. Eur J Heart Fail 2003; 5:599-606. (Pubitemid 38043963)
13. Fabbian F, De GA, Pala M, et al. Elevated NT-proBNP levels should be interpreted in elderly patients presenting with dyspnea. Eur J Intern Med 2011; 22:108-111.
14. Burke MA, Cotts WG. Interpretation of B-type natriuretic peptide in cardiac disease and other comorbid conditions. Heart Fail Rev 2007; 12:23-36. (Pubitemid 46629244)
15. Kaul S, Tei C, Hopkins JM, et al. Assessment of right ventricular function using two-dimensional echocardiography. Am Heart J 1984; 107:526-531. (Pubitemid 14167729)
16. Lang RM, Bierig M, Devereux RB, et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 2005; 18:1440-1463. (Pubitemid 41821197)
17. Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 1982; 143:29-36. (Pubitemid 12142173)
18. Shiina Y, Funabashi N, Lee K, et al. Right atrium contractility and right ventricular diastolic function assessed by pulsed tissue Doppler imaging can predict brain natriuretic peptide in adults with acquired pulmonary hypertension. Int J Cardiol 2009; 135:53-59.
19. Maisel A, Mueller C, Adams K, et al. State of the art: using natriuretic peptide levels in clinical practice. Eur J Heart Fail 2008; 10:824-839.
20. Troughton RW, Richards AM. B-type natriuretic peptides and echocardiographic measures of cardiac structure and function. JACC Cardiovasc Imaging 2009; 2:216-225.
21. Rutten FH, Cramer MJ, Zuithoff NP, et al. Comparison of B-type natriuretic peptide assays for identifying heart failure in stable elderly patients with a clinical diagnosis of chronic obstructive pulmonary disease. Eur J Heart Fail 2007; 9:651-659. (Pubitemid 46711268)
22. Kanat F, Vatansev H, Teke T. Diuretics, plasma brain natriuretic peptide and chronic obstructive pulmonary disease. Neth J Med 2007; 65:296-300. (Pubitemid 47520932)
23. Clerico A, Fontana M, Ripoli A, et al. Clinical relevance of BNP measurement in the follow-up of patients with chronic heart failure. Adv Clin Chem 2009; 48:163-179.
24. McKie PM, Burnett JC Jr. B-type natriuretic peptide as a biomarker beyond heart failure: speculations and opportunities. Mayo Clin Proc 2005; 80:1029-1036. (Pubitemid 41099389)
25. Kruger S, Graf J, Merx MW, et al. Brain natriuretic peptide predicts right heart failure in patients with acute pulmonary embolism. Am Heart J 2004; 147:60-65. (Pubitemid 38037398)
26. Zakynthinos E, Kiropoulos T, Gourgoulianis K, et al. Diagnostic and prognostic impact of brain natriuretic peptide in cardiac and noncardiac diseases. Heart Lung 2008; 37:275-285. (Pubitemid 351938694)
27. Corte TJ, Wort SJ, Gatzoulis MA, et al. Elevated brain natriuretic peptide predicts mortality in interstitial lung disease. Eur Respir J 2010; 36:819-825.
28. Andreassen AK, Wergeland R, Simonsen S, et al. N-terminal pro-B-type natriuretic peptide as an indicator of disease severity in a heterogeneous group of patients with chronic precapillary pulmonary hypertension. Am J Cardiol 2006; 98:525-529. (Pubitemid 44162883)
29. Troisi F, Greco S, Brunetti ND, et al. Right heart dysfunction assessed with echography, B-type natriuretic peptide and cardiopulmonary test in patients with chronic heart failure. J Cardiovasc Med (Hagerstown) 2008; 9:672-676.
30. Schoen SP, Zimmermann T, Kittner T, et al. NT-proBNP correlates with right heart haemodynamic parameters and volumes in patients with atrial septal defects. Eur J Heart Fail 2007; 9:660-666. (Pubitemid 46702818)
31. Caso P, Galderisi M, Cicala S, et al. Association between myocardial right ventricular relaxation time and pulmonary arterial pressure in chronic obstructive lung disease: analysis by pulsed Doppler tissue imaging. J Am Soc Echocardiogr 2001; 14:970-977. (Pubitemid 33095608)
32. Kjaergaard J, Akkan D, Iversen KK, et al. Right ventricular dysfunction as an independent predictor of short- and long-term mortality in patients with heart failure. Eur J Heart Fail 2007; 9:610-616. (Pubitemid 46702826)
33. Yap LB, Mukerjee D, Timms PM, et al. Natriuretic peptides, respiratory disease, and the right heart. Chest 2004; 126:1330-1336. (Pubitemid 39391268)